Stockreport

Forty Seven, Inc. to Present New Clinical and Preclinical Data on Magrolimab and FSI-174 at 61st ASH Annual Meeting

FORTY SEVEN  (FTSV) 
Last forty seven earnings: 11/12 07:01 am Check Earnings Report
PDF MENLO PARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Forty Seven, Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to act [Read more]